% | $
Quotes you view appear here for quick access.

Seattle Genetics, Inc. Message Board

mghmd 7 posts  |  Last Activity: Jun 7, 2016 12:41 PM Member since: Jan 22, 2000
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • mghmd mghmd Jun 7, 2016 12:41 PM Flag

    I am long RLYP and considered buying more today, but decided to wai tillt the next sales numbers; I am willing to pay more just to be sure that the sales trajectory is ok. However, can't dismiss Berens since he is a five star analyst according to tip ranks; on the other hand, 4 other 5 star analysts reiterated a buy within last 11 days

    Sentiment: Buy

  • Reply to

    Once again, shorts control

    by beverlyhistory1 May 27, 2016 3:18 PM
    mghmd mghmd May 27, 2016 4:34 PM Flag

    What could be better news then ZS9 being crushed-virtually no one expected this. And RLYP only went up 9%! The shorts have to be at work. If Valtessa shows some improved monthly numbers, the stock deserves to soar. Perhaps some MDs deferred prescribing Valtessa BECAUSE THEY THOUGHT THAT THEY would wait till ZS9 became available; there is a fairly limited group of docs who have to deal with chronic hperkalemia and they are likely to be knknowgdable about this issue. In the end, all hinges on whether Valtessa sales improve

  • This has been described as potentially being better than Pacira's(PCRX)'s medication. Although early in development, it could be a big +. Any thoughts from the board?

  • mghmd mghmd Feb 17, 2016 11:23 PM Flag

    In my opinion as a hematologist, the induction RR is not overwhelming. Scads of studies have had slightly favorable RR, but failed on the more CRUCIAL criteria of OS.The key issue is whether the OS data, if +, will be really clinically meanigful, rather then just statistically significant. I own a little, but wouldn't bet the farm.,

  • Reply to

    Is there light at the end of the tunnel?

    by scientist206 Feb 9, 2016 1:02 PM
    mghmd mghmd Feb 11, 2016 12:01 PM Flag

    NEWTOWN, Pa., Dec. 07, 2015 (GLOBE
    NEWSWIRE) -- Onconova Therapeutics,
    Inc. (ONTX), a clinical-stage biopharmaceutical
    company focused on discovering and
    developing novel products to treat cancer,
    today announced the enrollment of the first
    patient in the INSPIRE trial for IV rigosertib
    as a treatment for higher-risk myelodysplastic
    syndromes (HR-MDS) after failure of
    hypomethylating agent (HMA) therapy.
    "There is a significant unmet medical need
    in patients who have failed treatment with an HMA, the only available therapy for HRMDS,”
    said Dr. Guillermo Garcia-Manero, lead investigator for the INSPIRE trial and Chief
    of the Section of Myelodysplastic Syndromes at The University of Texas MD Anderson
    Cancer Center. “In previous clinical studies, rigosertib demonstrated positive results in
    HR-MDS patients with very poor prognosis. The INSPIRE trial is designed to assess the
    effects of IV rigosertib in these HR-MDS patients who have a short life-span and no effective
    therapies currently available.”
    The INSPIRE trial is a global, multi-center, randomized controlled study to assess the efficacy
    and safety of IV rigosertib in HR-MDS patients under 80 years of age who had progressed
    on, or failed to respond to, or relapse after previous treatment with HMAs. The
    trial will enroll approximately 225 patients randomized at a 2:1 ratio into two treatment
    arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive
    Care. The primary endpoint of INSPIRE is overall survival and an interim analysis
    is anticipated.
    Clinical Trial Applications (CTAs) and/or site initiation activities for INSPIRE have begun in

  • Reply to

    Is there light at the end of the tunnel?

    by scientist206 Feb 9, 2016 1:02 PM
    mghmd mghmd Feb 11, 2016 11:56 AM Flag

    You have to be patient. The ph3 study, which has just started, for a "derisked" group of patients with myelodysplastic syndrome,, has a high likelihood of being successful. They have selected the group of patients who had the best response in ph2 for the ph3 study, and this is what I mean about being derisked. The study chairman is the head of the Myelodysplastic Section at MD Anderson, probably the best cancer hospital. and he spoke enthusiastically about the ph2 data after the presentation at ASH 2015.The company has strong support from Baxalta,,so I don't think you have to worry about bankruptcy.

  • article in SA today that rlyp has big advantage over Zy.. because it is free of sodium while Z adds a significant
    amount of sodium to a population of patients in whom it could have an adverse effect due to rise in BP. Can anyone provide an authoritative comment?

37.59-2.48(-6.19%)Jun 24 4:00 PMEDT